Ed Silverman
STAT
Mountain View, CA, United States
Contact Ed
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Ed:
Democratic lawmakers press pharmacy chains on abortion pill access
Pharmacies are in "a little bit of a damned if you do, damned if you don’t situation," one expert said. . → Read More
Pharmalittle: Novo to cut some insulin prices by up to 75%; Veterans Administration to cover new Alzheimer's treatment
Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step. → Read More
Novo Nordisk to lower insulin prices by up to 75% amid growing pressure
Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products by up to 75%. → Read More
Veterans Health Administration will cover the newest Alzheimer’s drug
In an unexpected move, the Veterans Health Administration announced Monday that it will widely cover a new Alzheimer’s treatment, even as Medicare has decided to wait for additional data about the medicine before taking the same step. → Read More
Pharmalittle: Biogen exec who quarterbacked Aduhelm leaves; Pfizer to buy Seagen for $43 billion
The Biogen senior executive who supervised the development and controversial approval of the Alzheimer’s treatment Aduhelm left the company last week. → Read More
Insulin for $20 a vial? Sanders pushes bill for price caps on the diabetes treatment
Sen. Bernie Sanders has introduced a bill that would place a $20 cap on all insulin, a move designed to drastically lower costs for millions of Americans. → Read More
Pharmalittle: Pharmacies are battlegrounds in the abortion debate; Lilly Alzheimer’s drug failed to prevent memory loss in study
An experimental Eli Lilly drug failed to prevent memory loss in a study of healthy older people with a high risk of developing clinical Alzheimer’s disease. → Read More
Pharmalittle: FDA head wants to get rid of advisory panel votes; premature-birth drug is finally withdrawn
Novo Nordisk’s injectable drug Wegovy has been cleared for use on the National Health Service in England by a cost-effectiveness agency. → Read More
Controversial drug for premature birth is withdrawn by manufacturer after battle with FDA
"It is crucial we learn from this fiasco and make changes to ensure that nothing like this happens again" said Adam Urato, a physician. → Read More
Pharmalittle: Biden proposes expanding Medicare drug-price negotiation; Weight Watchers moves into obesity drug market
The White House will propose expanding authority to negotiate what Medicare pays for more drugs than the limited number approved last year. → Read More
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. → Read More
FDA cites Cipla for placing important manufacturing records in the trash
The FDA cited one of the world's largest generic drug makers for keeping important manufacturing records in bags in a truck. → Read More
Pharmalittle: How Lilly’s cuts will affect other efforts to lower insulin prices; pharma rebukes U.K. over clawbacks
Lilly's slashing of prices for some of its insulin products raised questions about what will happen to other efforts to provide low-cost insulin. → Read More
Pharmalittle: FDA panel backs a GSK vaccine for RSV; opioid wholesalers cleared of liability to Georgia families
A FDA advisory panel backed a GSK respiratory syncytial virus vaccine, setting it up for a race with Pfizer to have the first approved U.S. shot against RSV. → Read More
Eli Lilly cuts prices for some insulin products, but some are wary
Eli Lilly, one of the largest makers of insulin, said it would make dramatic cuts to the prices of several of its older insulin products in an effort to lower costs for consumers whose insulin is not fully paid for by insurance. → Read More
FDA is petitioned to boost enforcement of trial sponsors that fail to register studies or report results
An organization that promotes and studies clinical trial disclosure has petitioned the U.S. Food and Drug Administration to take several steps to boost its enforcement of wayward trial sponsors and investigators that fail to register studies and report results. → Read More
Pharmalittle: Pfizer in talks to acquire Seagen; U.S. trade rep urged not to sanction countries that sidestep Vertex patents
Pfizer is in talks to acquire Seagen, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies. → Read More
U.S. Trade Rep urged not to sanction countries if they sidestep patents on Vertex cystic fibrosis drugs
Advocacy groups are asking the U.S. Trade Representative not to sanction or pressure four governments if they grant requests from cystic fibrosis patients to sidestep patents on a pricey medicine. → Read More
A dozen states sue the FDA in hopes of easing abortion pill restrictions
“Mifepristone is safer than Tylenol. Despite that, the FDA imposes needless restrictions reserved for some of the highest risk drugs, including fentanyl,” Connecticut Attorney General William Tong said. → Read More
Little transparency, lots of waste: NIH funds pediatric research, but many trials results go unpublished
A new analysis found the results of many pediatric clinical trials go unpublished. → Read More